CSRxP Praises Gottlieb For Leadership On Drug Pricing

Mar 6, 2019

FDA Commissioner Was Invaluable Voice In Favor Of Market-Based Solutions To

Increase Competition & Lower Drug Prices

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Tuesday praising Food and Drug Administration (FDA) Commissioner Gottlieb for his efforts to support and advance market-based solutions to the prescription drug pricing crisis during his tenure.  Earlier today, Gottlieb announced he would resign as FDA Commissioner.

“Commissioner Gottlieb has been an invaluable voice in Washington in the fight to lower the price of prescription drugs and hold brand name pharmaceutical manufacturers accountable for their anti-competitive tactics,” said CSRxP executive director Lauren Aronson.  “Commissioner Gottlieb’s commitment to protecting patient safety, while encouraging solutions to bring more generics and biosimilars into the market, has been critical to advancing sensible, market-based solutions to benefit all Americans.”

CSRxP noted several areas where Gottlieb has demonstrated important leadership in the drug pricing arena:

  • Helping to curb Risk Evaluation and Mitigation Strategy (REMS) abuse to improve patient safety and ensure medicines are accessible for patients.
  • Promoting biosimilars through the FDA’s Biosimilars Action Plan.
  • Elevating awareness of brand manufacturer ‘gaming’ of FDA rules to deny would-be generic competitors the ability to purchase samples of brand-name drugs necessary to conduct the FDA-required testing and bring more affordable medicines to market.
  • Supporting the bipartisan CREATES Act that would crack down on anti-competitive tactics employed by brand name drug makers to keep generic competitors out of the market.